Key Points
- To delineate the cellular pathways causing endothelial dysfunction in diabetes and hypertension and evaluate therapeutic strategies to mitigate vascular complications.
- Synthesized molecular mechanisms linking metabolic and hemodynamic stress to endothelial impairment.
- Evaluated therapeutic pathways targeting vascular tone regulation, reactive oxygen species reduction, and renin-angiotensin system inhibition.
- Endothelial dysfunction develops through reduced nitric oxide bioavailability coupled with elevated levels of angiotensin II, endothelin-1, reactive oxygen species, and cyclooxygenase metabolites.
- Impaired endothelial signaling drives increased vascular tone, arterial stiffening, and cardiac remodeling, directly contributing to microvascular, macrovascular, and renal pathology.
- Therapies utilizing antioxidants, renin-angiotensin system inhibitors, or agents that stimulate endothelial nitric oxide synthase demonstrate potential to reverse vascular injury and reduce cardiovascular events.
Structured PICO
PPopulationPatients with diabetes and hypertension
IInterventionTherapies targeting reactive oxygen species (antioxidants, renin-angiotensin system inhibitors) or increasing endothelial nitric oxide synthase activity
OOutcomeCardiovascular morbidity and mortality
Endothelial dysfunction is a central mechanism driving vascular complications in diabetes and hypertension, highlighting it as a potential therapeutic target.